Dr. med. Melanie Hagen

Department of Medicine 3 – Rheumatology and Immunology

Physical Function of RA patients Tapering Treatment—A Post Hoc Analysis of the Randomized Controlled RETRO Trial (2023) Stephan M, Tascilar K, Yalcin-Mutlu M, Hagen M, Haschka J, Reiser M, Hartmann F, et al. Journal article Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Valor L, Tascilar K, Krönke G, et al. Conference contribution Ultrasound-detected inflammation is more common in clinically manifest hand osteoarthritis than in painless bony enlarged finger joints: subanalysis of the population-based Bruneck study (2022) Gasperi N, Schreiber N, Bosch P, Adinolfi A, Kleyer A, Hagen M, Gasperi C, et al. Journal article IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritis. (2022) Sokolova M, Hagen M, Bang H, Schett G, Rech J, Steffen U Journal article Accuracy and usability of a diagnostic decision support system in the diagnosis of three representative rheumatic diseases: a randomized controlled trial among medical students (2021) Knitza J, Tascilar K, Gruber E, Kaletta H, Hagen M, Liphardt AM, Schenker H, et al. Journal article Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial (2021) Knitza J, Mohn J, Bergmann C, Kampylafka E, Hagen M, Bohr D, Morf H, et al. Journal article Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs (2021) Vodencarevic A, Tascilar K, Reiser M, Hueber A, Haschka J, Bayat S, Meinderink T, et al. Journal article Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial (2021) Tascilar K, Hagen M, Kleyer A, Simon D, Reiser M, Hueber A, Manger B, et al. Journal article Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients (2021) Rech J, Hueber A, Ostergaard M, Tascilar K, Hagen M, Mendez LV, Kleyer A, et al. Conference contribution